SEC Form 10-Q filed by MiMedx Group Inc

4/30/25 4:00:52 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MDXG alert in real time by email

mdxg-20250331

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the

Quarterly Period Ended

March 31, 2025


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________________to______________________

Commission File Number 001-35887

MIMEDX GROUP, INC.

(Exact name of registrant as specified in its charter)


Florida						26-2792552
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)


1775 West Oak Commons Ct NE Marietta, GA						30062
(Address of principal executive offices)						(Zip Code)

(770) 651-9100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	MDXG	The Nasdaq Stock Market

Securities registered pursuant to Section 12(g) of the Act: None.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer x

Accelerated filer ¨

Non-accelerated filer ¨

Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No x

There were 147,702,140 shares of the registrant’s common stock, par value $0.001 per share, outstanding as of April 24, 2025.

Table of Contents


Part I FINANCIAL INFORMATION
Item 1	Financial Statements (Unaudited)
	Condensed Consolidated Balance Sheets	5
	Condensed Consolidated Statements of Operations	6
	Condensed Consolidated Statements of Stockholders’ Equity	7
	Condensed Consolidated Statements of Cash Flows	8
	Notes to the Condensed Consolidated Financial Statements	9
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3	Quantitative and Qualitative Disclosures About Market Risk	22
Item 4	Controls and Procedures	22
Part II OTHER INFORMATION
Item 1	Legal Proceedings	23
Item 1A	Risk Factors	23
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3	Defaults upon Senior Securities	23
Item 4	Mine Safety Disclosures	23
Item 5	Other Information	23
Item 6	Exhibits	24
Signatures		24

Explanatory Note and Important Cautionary Statement Regarding Forward-Looking Statements

As used herein, the terms “MIMEDX,” the “Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.

Certain statements made in this Quarterly Report on Form 10-Q (this “Quarterly Report”) are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and section 21E of the Securities Exchange Act of 1934, as amended. All statements herein relating to events or results that may occur in the future are forward-looking statements, including, without limitation, statements regarding the following:

•our strategic focus and current business priorities, including broadening of our product portfolio, and our ability to implement these priorities, including as a result of our no longer being able to market certain products in our portfolio;

•our expectations regarding costs relating to compliance with regulatory requirements;

•our expectations regarding capital allocation;

•our expectations regarding future growth;

•our expectations regarding the outcome of pending litigation and investigations;

•our expectations regarding future income tax liability;

•demographic and market trends; and

•our ability to compete effectively.

Forward-looking statements generally can be identified by words such as “expect,” “will,” “change,” “intend,” “seek,” “target,” “future,” “plan,” “continue,” “potential,” “possible,” “could,” “estimate,” “may,” “anticipate,” “to be” and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company’s operations and may cause the Company’s actual actions, results, financial condition, performance or achievements to differ materially from any future actions, results, financial condition, performance or achievements expressed or implied by any such forward-looking statements. Factors that may cause such a difference include, without limitation, those discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 (our “2024 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on February 26, 2025 and those discussed in Part II, Item 1A, Risk Factors, if any.

Unless required by law, the Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained in this Quarterly Report is specifically qualified in its entirety by the aforementioned factors. Readers are advised to carefully read this Quarterly Report in conjunction with the important disclaimers set forth above prior to reaching any conclusions or making any investment decisions and not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this Quarterly Report with the SEC.

Estimates and Projections

This Quarterly Report includes certain estimates, projections and other statistical data. These estimates and projections reflect management’s best estimates based upon currently available information and certain assumptions we believe to be reasonable as of the date of this Quarterly Report. These estimates are inherently uncertain, subject to risks and uncertainties, many of which are not within our control, have not been reviewed by our independent auditors and may be revised as a result of management’s further review. In addition, these estimates and projections are not a comprehensive statement of our financial results, and our actual results may differ materially from these estimates and projections due to developments that may arise between now and the time the results are final. There can be no assurance that the estimates will be realized, and our results may vary significantly from the estimates, including as a result of unexpected issues in our business and operations. Accordingly, you should not place undue reliance on such information. Projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

(unaudited)


	March 31, 2025		December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$	106,431	$	104,416
Accounts receivable, net	62,288		55,828
Inventory	24,070		23,807
Prepaid expenses	5,351		5,018
Other current assets	1,972		2,817
Total current assets	200,112		191,886
Property and equipment, net	5,773		5,944
Right of use asset	5,299		5,606
Deferred tax asset, net	27,685		28,306
Goodwill	19,441		19,441
Intangible assets, net	11,062		11,626
Other assets	1,048		1,106
Total assets	$	270,420	$	263,915
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long term debt	1,125		1,000
Accounts payable	8,868		7,409
Accrued compensation	18,744		23,667
Accrued expenses	9,447		9,012

Other current liabilities	4,435		4,507
Total current liabilities	42,619		45,595
Long term debt, net	17,533		17,830
Other liabilities	7,492		7,383
Total liabilities	$	67,644	$	70,808

Stockholders' equity

Common stock; $0.001 par value; 250,000,000 shares authorized; 147,607,622 issued and outstanding at March 31, 2025 and 146,932,032 issued and outstanding at December 31, 2024	148		147
Additional paid-in capital	286,864		284,219

Accumulated deficit	(84,236)		(91,259)
Total stockholders' equity	202,776		193,107
Total liabilities and stockholders’ equity	$	270,420	$	263,915

See notes to unaudited condensed consolidated financial statements

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)


	Three Months Ended March 31,
	2025		2024

Net sales	$	88,205	$	84,709
Cost of sales	16,558		12,987
Gross profit	71,647		71,722

Operating expenses:
Selling, general and administrative	59,969		55,129
Research and development	3,328		2,841
Investigation, restatement and related	—		311
Amortization of intangible assets	99		189
Impairment of intangible assets	—		54
Operating income	8,251		13,198

Other expense, net
Interest income (expense), net	506		(1,690)
Other expense, net	(145)		(99)
Income from continuing operations before income tax	8,612		11,409
Income tax provision	(1,589)		(2,348)
Net income from continuing operations	7,023		9,061
Income from discontinued operations, net of tax	—		200
Net income	$	7,023	$	9,261


Basic net income per common share:
Continuing operations:	$	0.05	$	0.06
Discontinued operations:	—		0.00
Basic net income per common share	$	0.05	$	0.06

Diluted net income per common share:
Continuing operations	$	0.05	$	0.06
Discontinued operations	—		0.00
Diluted net income per common share	$	0.05	$	0.06

Weighted average common shares outstanding - basic	147,272,324		146,404,587
Weighted average common shares outstanding - diluted	149,677,452		150,028,107

See notes to unaudited condensed consolidated financial statements

MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share data)
(unaudited)


	Common Stock Issued			Additional Paid- In		Accumulated
	Shares	Amount		Capital			Deficit		Total
Balance at December 31, 2024	146,932,032	$	147	$	284,219		$	(91,259)	$	193,107

Share-based compensation expense	—	—		4,259			—		4,259

Employee stock purchase plan	149,457	—		848			—		848
Issuance of restricted stock, net	526,133	1		(2,462)			—		(2,461)



Net income	—	—		—			7,023		7,023
Balance at March 31, 2025	147,607,622	$	148	$	286,864		$	(84,236)	$	202,776


	Common Stock Issued			Additional Paid- In		Accumulated
	Shares	Amount		Capital			Deficit		Total
Balance at December 31, 2023	146,227,639	$	146	$	276,249		$	(133,678)	$	142,717

Share-based compensation expense	—	—		4,340			—		4,340
Exercise of stock options	109,920	—		766			—		766
Issuance of restricted stock, net	1,069,254	2		(2,152)			—		(2,150)


Employee stock purchase plan	121,783	—		797			—		797
Net Income	—	—		—			9,261		9,261

Balance at March 31, 2024	147,528,596	$	148	$	280,000		$	(124,417)	$	155,731

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

(unaudited)


	Three Months Ended March 31,
	2025		2024
Cash flows from operating activities:
Net income from continuing operations	$	7,023	$	9,061
Adjustments to reconcile net income from continuing operations to net cash flows provided by operating activities from continuing operations:
Share-based compensation	4,262		4,340
Depreciation and amortization	3,203		747
Deferred income taxes	621		2,031
Credit loss expense	742		199

Non-cash lease expenses	307		317
Amortization of deferred financing costs	135		69
Accretion of asset retirement obligation	24		22
Loss on extinguishment of debt	—		1,401


Loss on fixed asset disposal	—		185



Change in the fair value of earnout liability	7		—
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(7,203)		(3,344)
Inventory	(263)		(2,941)
Prepaid expenses	(333)		(471)
Other assets	(699)		(1,001)
Accounts payable	1,460		283
Accrued compensation	(4,073)		(4,440)
Accrued expenses	(73)		522
Other liabilities	159		(195)
Net cash flows from operating activities of continuing operations	5,299		6,785
Net cash flows used in operating activities of discontinued operations	—		(807)
Net cash flows provided by operating activities	5,299		5,978

Cash flows from investing activities:

Purchases of equipment	(377)		(1,144)
Patent application costs	(29)		120
Cash paid for acquisitions	—		(5,000)

Net cash flows used in investing activities	(406)		(6,024)

Cash flows from financing activities:
Stock repurchased for tax withholdings on vesting of restricted stock	(2,458)		(2,152)
Principal payment on Citizens Term Loan Facility	(250)		(250)
Profit Share Payment	(170)		—
Proceeds from Citizens Revolving Credit Facility	—		30,000
Proceeds from Citizens Term Loan Facility	—		19,783
Prepayment premium on Hayfin term loan	—		(500)
Deferred financing cost	—		(1,101)
Repayment of Hayfin term loan	—		(50,000)
Repayment of Citizens Revolving Credit Facility	—		(30,000)

Proceeds from exercise of stock options	—		766
Principal payments on finance lease	—		(13)
Net cash flows used in financing activities	(2,878)		(33,467)

Net change in cash	2,015		(33,513)

Cash and cash equivalents, beginning of period	104,416		82,000
Cash and cash equivalents, end of period	$	106,431	$	48,487

See notes to unaudited condensed consolidated financial statements

MIMEDX GROUP, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024

1.Nature of Business

MiMedx Group, Inc. (together with its subsidiaries, except where the context otherwise requires, “MIMEDX,” or the “Company”) is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. All of the Company’s products sold in the United States are regulated by the United States Food and Drug Administration (“FDA”).

The Company’s product portfolio and product development focuses on Wound and Surgical markets.

The Company’s business is focused primarily on the United States, but the Company also has an emerging commercial presence in several international locations, including Japan.

2.Significant Accounting Policies

Please see Note 2, Significant Accounting Policies, to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on February 26, 2025 for a description of all significant accounting policies.

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included. The operating results for the three months ended March 31, 2025 and 2024 are not necessarily indicative of the results that may be expected for the full fiscal year. The balance sheet as of December 31, 2024 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2024 Form 10-K.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.

Use of Estimates

GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported condensed consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimates of impairment for goodwill and intangible assets, estimates of useful lives for intangible assets, estimates of loss for contingent liabilities, estimate of allowance for doubtful accounts, estimates of fair value of and the probable achievement of performance conditions associated with share-based payment awards, estimates of returns and allowances, estimate of fair value of the remaining Profit Share Payments (as defined below), and valuation of deferred tax assets.

Recently Issued Accounting Standards Not Yet Adopted

Accounting Standards Update 2023-09 - Income Taxes

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Improvement to Income Tax Disclosures (Topic 740)”, which requires additional disclosures for income tax rate reconciliations, income taxes paid, and certain other tax disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. Adoption is required for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

Accounting Standards Update 2024-04 - Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures

In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40),” which requires disaggregated disclosure of certain income statement expenses within the footnotes to the financial statements. ASU 2024-03 is intended to address requests from investors for more detailed information about the types of expenses in commonly presented expense captions such as cost of sales, selling, general and administrative expenses, and research and development. Adoption is required for the annual periods beginning after December 15, 2026. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

All other ASUs issued and not yet effective as of March 31, 2025, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s current and future financial position and results of operations.

3. Accounts Receivable, Net

Accounts receivable, net, consisted of the following (in thousands):


	March 31, 2025		December 31, 2024
Accounts receivable, gross	$	66,162	$	58,960
Less: allowance for doubtful accounts	(3,874)		(3,132)
Accounts receivable, net	$	62,288	$	55,828

Activity related to the Company’s allowance for doubtful accounts for the three months ended March 31, 2025 and 2024 were as follows (in thousands):


Balance at December 31, 2024	$	3,132
Bad debt expense	742
Write-offs	—
Balance at March 31, 2025	$	3,874


Balance at December 31, 2023	$	3,144
Bad debt expense	199
Write-offs	(77)
Balance at March 31, 2024	$	3,266

4. Inventory

Inventory consisted of the following (in thousands):


	March 31, 2025		December 31, 2024
Raw materials	$	1,143	$	1,010
Work in process	4,526		8,580
Finished goods	18,401		14,217


Inventory	$	24,070	$	23,807

5. Property and Equipment, Net

Property and equipment, net, consisted of the following (in thousands):


	March 31, 2025		December 31, 2024
Laboratory and clean room equipment	$	15,739	$	15,549
Furniture and equipment	1,968		1,951
Leasehold improvements	8,439		8,213
Construction in progress	622		686
Asset retirement cost	876		867

Property and equipment, gross	27,644		27,266
Less: accumulated depreciation and amortization	(21,871)		(21,322)
Property and equipment, net	$	5,773	$	5,944

Depreciation expense (in thousands):


	Three Months Ended March 31,
	2025		2024
Depreciation Expense	$	558	$	558

6. Intangible Assets, Net

Intangible assets, net, are summarized as follows (in thousands):


	March 31, 2025						December 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Amortized intangible assets
Patents and know-how	$	10,407	$	(8,574)	$	1,833	$	10,320	$	(8,488)	$	1,832
Licenses	1,000		(117)		883		1,000		(104)		896
Customer and supplier relationships	7,659		(1,530)		6,129		7,659		(1,147)		6,512
Tradenames and trademarks1	4,989		(4,013)		976		2,937		(1,850)		1,087
Total amortized intangible assets	$	24,055	$	(14,234)	$	9,821	$	21,916	$	(11,589)	$	10,327

Unamortized intangible assets:
Tradenames and trademarks	$	1,008			$	1,008	$	1,008			$	1,008
Patents in Process	233				233		291				291
Total intangible assets	$	25,296			$	11,062	$	23,215			$	11,626

1 Reflects the Celera tradename, which is amortized on a basis consistent with the consumption of the trademark’s economic benefits.

The Company recognized no and $0.1 million of impairment of intangible assets during the three months ended March 31, 2025 and 2024, respectively. The impairment during three months ended March 31, 2024 related to abandoned patents.

Expected future amortization of intangible assets as of March 31, 2025, is as follows (in thousands):


Year ending December 31,	Estimated Amortization Expense
2025 (excluding the three months ended March 31, 2025)	$	2,420
2026	1,771
2027	1,771
2028	1,768
2029	612
Thereafter	1,479
Total amortized intangible assets	$	9,821

7. Accrued Expenses

Accrued expenses consisted of the following (in thousands):


	March 31, 2025		December 31, 2024
Commissions to sales agents	$	3,741	$	3,843
Accrued rebates	1,142		1,223
Estimated sales returns	1,723		1,990
Legal costs	1,206		459
Accrued group purchasing organization fees	712		411

Accrued inventory receipts	615		871
Other	308		215
Accrued expenses	$	9,447	$	9,012

8. Long Term Debt, Net

Citizens Credit Agreement

On January 19, 2024, the Company entered into the Citizens Credit Agreement, which provided the Company with $30.0 million under the Revolving Credit Facility and $20.0 million under the Term Loan Facility. Proceeds from the initial drawings under the Credit Facilities together with cash on hand were used to repay in full the $50.0 million principal amount and other outstanding obligations under a previous loan agreement to pay related fees, premiums, costs and expenses (collectively with the entry into the Citizens Credit Agreement and the initial borrowings thereunder, the “Debt Refinancing Transactions”). On February 27, 2024, the Company repaid the initial $30.0 million drawing under the Revolving Credit Facility and had no outstanding borrowings under this facility as of March 31, 2025. The Term Loan Facility matures on January 19, 2029 (the “Maturity Date”).

Borrowings under the Citizens Credit Agreement bear interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings, plus a fallback provision of 0.1%. The Term Loan Facility carried an interest rate of 6.7% as of March 31, 2025.

The balances of the Term Loan Facility as of March 31, 2025 and December 31, 2024 were as follows (in thousands):


	March 31, 2025				December 31, 2024
	Current portion of long term debt		Long term debt, net		Current portion of long term debt		Long term debt, net
Outstanding principal	1,125		17,625		1,000		18,000
Deferred financing costs	—		(18)		—		(33)
Original issue discount	—		(74)		—		(137)
Long term debt, net	$	1,125	$	17,533	$	1,000	$	17,830

Interest expense related to the Term Loan Facility and the Hayfin Term Loan included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):


	Three Months Ended March 31,
	2025		2024
Stated interest	$	317	$	661
Amortization of deferred financing costs	15		29
Accretion of original issue discount	62		13
Interest expense	$	394	$	703

Interest expense related to the Revolving Credit Facility included in Interest income (expense), net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):


	Three Months Ended March 31,
	2025		2024
Commitment fee	$	26	$	30
Amortization of deferred financing costs	16		16
Accretion of original issue discount	42		42
Interest expense	$	84	$	88

A summary of principal payments due on the Term Loan Facility, by year, from March 31, 2025 through maturity are as follows (in thousands):


Year ending December 31,	Principal
2025 (excluding the three months ended March 31, 2025)	$	750
2026	1,500
2027	1,500
2028	2,000
2029	13,000
Outstanding principal	$	18,750

As of March 31, 2025, the fair value of the Term Loan Facility was $19.0 million. This valuation was calculated based on a series of Level 2 and Level 3 inputs, including a discount rate based on the credit risk spread of debt instruments of similar risk character in reference to U.S. Treasury instruments with similar maturities, with an incremental risk premium for risk factors specific to the Company. Fair value was calculated by discounting the remaining cash flows associated with the Term Loan Facility to March 31, 2025 using this discount rate.

9. Net Income Per Common Share

Net income per common share is calculated using two methods: basic and diluted.

Basic Net Income Per Common Share

The following table provides a reconciliation of net income from continuing operations and calculation of basic net income (loss) per common share for each of the three months ended March 31, 2025 and 2024 (in thousands, except share and per share amounts). In the presentation below “Net Income from continuing operations” and “Net Income from continuing operations available to common shareholders” represent the same value.


	Three Months Ended March 31,
	2025		2024
Net income from continuing operations	$	7,023	$	9,061
Income from discontinued operations, net of tax	—		200
Net income	7,023		9,261







Weighted average common shares outstanding	147,272,324		146,404,587
Basic net income per common share:
Continuing operations	0.05		$	0.06
Discontinued operations	—		$	0.00
Basic net income per common share	$	0.05	$	0.06

Diluted Net Income Per Common Share

The following table sets forth the computation of diluted net income per common share (in thousands, except share and per share amounts):


	Three Months Ended March 31,
	2025		2024







Net income from continuing operations	7,023		9,061
Income from discontinued operations, net of tax	—		200
Net income	7,023		9,261
Weighted average shares outstanding	147,272,324		146,404,587
Adjustments:
Potential common shares

Restricted stock unit awards	1,565,979		2,016,109
Outstanding stock options	598,798		1,499,970
Performance stock unit awards	230,549		106,802
Employee stock purchase plan	9,802		639
Total adjustments	2,405,128		3,623,520
Weighted average shares outstanding adjusted for potential common shares	149,677,452		150,028,107
Diluted net income per common share:
Continuing operations	$	0.05	$	0.06
Discontinued operations	—		0.00
Diluted net income per common share	$	0.05	$	0.06

10. Income Taxes

On a continuing operations basis, the effective tax rates for the Company were 18.5% and 20.6% for the three months ended March 31, 2025 and 2024, respectively.

Restricted stock vestings favorably impacted the effective tax rate for the three ended March 31, 2025 and 2024.

11. Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities

Selected cash payments, receipts, and non-cash activities are as follows (in thousands):


	Three Months Ended March 31,
	2025		2024
Cash paid for interest	$	343	$	1,403
Cash paid for income taxes	23		8
Non-cash activities:
Minimum Profit Share Payments pursuant to TELA APA	—		2,731
Right of use assets arising from operating lease liabilities	—		1,820
Issuance of shares pursuant to employee stock purchase plan	848		797
Purchases of equipment in accounts payable	—		626
Consideration payable to TELA	—		366
Unpaid deferred financing costs	—		149

12. Commitments and Contingencies

TELA and Regenity Agreements

On March 15, 2024, the Company entered into an Asset Purchase Agreement (the “TELA APA”) with TELA Bio, Inc. (“TELA”) to obtain exclusive rights to sell and market a 510(k)-cleared collagen particulate xenograft product in the United States. Pursuant to the TELA APA, the Company is required to make additional payments (the “Profit Share Payments”) of between a minimum of $3.0 million and a maximum of $7.0 million based on MIMEDX’s net sales of the product over the two years following its commercialization of the product, which occurred during the second quarter of 2024. The company’s remaining obligation of Profit Share Payments to TELA as of March 31, 2025 is $2.7 million.

As of March 31, 2025, the fair value for the minimum amount of Profit Share Payments was $2.5 million. This amount reflects the anticipated timing of such Profit Share Payments, discounted to present value at a discount rate approximating the Company’s borrowing rate plus a risk premium, all of which reflect Level 3 inputs. This amount is reflected as part of other current liabilities and other liabilities in the unaudited condensed consolidated balance sheet.

Litigation and Regulatory Matters

In the ordinary course of business, the Company and its subsidiaries may be a party to pending and threatened legal, regulatory, and governmental actions and proceedings (including those described below). In view of the inherent difficulty of predicting the outcome of such matters, particularly where the plaintiffs or claimants seek very large or indeterminate damages or where the matters present novel legal theories or involve a large number of parties, the Company generally cannot predict what the eventual outcome of the pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the eventual recovery, loss, fines or penalties related to each pending matter may be. The Company's unaudited condensed consolidated balance sheet as of March 31, 2025 reflects the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. For more information regarding the Company’s legal proceedings, refer to Note 18, “Commitments and Contingencies” in the 2024 Form 10-K.

The Company has no accrual for potential losses related to legal matters as of March 31, 2025. The Company made no payments toward the resolution of legal matters involving the Company during the three months ended March 31, 2025 or 2024.

The following is a description of certain litigation and regulatory matters to which the Company is a party:

AXIOFILL

The Company received a Warning Letter on December 21, 2023, relating to the inspections and classification of AXIOFILL. The Company received a determination letter in March 2024 reaffirming the FDA’s position that AXIOFILL does not meet the regulatory classification requirements of a Human Cell, Tissue or Cellular or Tissue-based Product under Section 361 of the Public Health Service Act. The Company strongly disagrees with this determination. On March 25, 2024, MIMEDX filed suit in the U.S. District Court for the Northern District of Georgia alleging violations of the Administrative Procedure Act and asking the Court to vacate FDA’s designation, declare FDA’s designation as arbitrary, capricious, an abuse of discretion, and

contrary to law, and declare that AXIOFILL meets the criteria to be regulated under Section 361 of the Public Health Services Act. The parties have each filed motions for summary judgment in the case, and the oral argument on the summary judgment motions was held on March 20, 2025.

13. Revenue

MIMEDX has two product categories: (1) Wound, which reflects products typically used in Advanced Wound Care settings, including the treatment of chronic, non-healing wounds, and (2) Surgical, which reflects products principally used in surgical settings, including the closure of acute wounds or to protect and reinforce tissues and/or regions of interest. The Company manages its product portfolio and pipeline based upon opportunities in each of these settings.

Below is a summary of net sales by product line (in thousands):


	Three Months Ended March 31,
	2025		2024
Wound	$	56,073	$	57,049
Surgical	32,132		27,660
Total	$	88,205	$	84,709

The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three months ended March 31, 2025 or 2024.

14. Segment Information

The Company determines its operating segment based on how the Chief Operating Decision Maker (“CODM”) reviews the business and makes resource allocation decisions. The Company concluded that Joseph Capper, the Company’s Chief Executive Officer, is the CODM.

The Company has a single operating segment, which has not been aggregated with other operating segments.

The CODM uses several measures of profit or loss to assess Company performance and allocate resources. Of these measures, net income is the measure that most aligns to GAAP. Other measures used by the CODM includes adjusted earnings before interest, taxes, depreciation and amortization. The CODM assesses actual results against budgets and forecasts, and uses this information to inform various strategic investments into the Company’s operations, including headcount and compensation.

Each financial statement caption included on the condensed consolidated statements of operations reflects a significant segment expense evaluated by the CODM. In addition to this, the CODM also evaluates selling and marketing expense and general and administrative expense, both of which are components of selling, general, and administrative expense on the condensed consolidated statements of operations.

The below table presents selling and marketing and general administrative expense (amounts in thousands):


	Three Months Ended March 31,
	2025		2024
Selling and marketing	$	46,861	$	44,477
General and administrative	13,108		10,652
Selling, general and administrative	$	59,969	$	55,129

Below is a breakout of interest expense and interest income (amounts in thousands):


	Three Months Ended March 31,
	2025		2024
Interest income	$	984	$	684
Interest expense	(478)		(2,374)
Interest expense, net	$	506	$	(1,690)

To see depreciation expense, amortization expense, income tax expense, and significant noncash items for this segment please refer to Note 5, Property and Equipment, Net, Note 6, Intangible Assets, Net, Note 10, Income taxes, Note 11, Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities, respectively.

The CODM is not provided and does not review segment assets at a different asset level or category than the presentation on the consolidated balance sheet.

15. Discontinued Operations

Disbanding of Regenerative Medicine Business Unit

In the second quarter of 2023, the Company announced the disbanding of its Regenerative Medicine reportable segment and the suspension of its Knee Osteoarthritis clinical trial program. The announcement reflected the abandonment of the Company’s efforts to pursue a Biological License Application for its micronized dehydrated human amnion chorion membrane product and a major definitive strategic shift in the Company’s focus towards its continuing commercial pipeline as its primary source of value creation.

The Company completed the regulatory obligations associated with the clinical trial during the fourth quarter of 2023, at which time material run-off operations had ceased and Regenerative Medicine met the criteria for presentation as a discontinued operation.

Financial Statement Impact of Discontinued Operations

The income and expenses of the discontinued operation have been classified as income (loss) from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2025 and 2024 as follows (in thousands):


	Three Months Ended March 31,
	2025		2024
Research and development expense	$	—	$	(200)
Income from discontinued operations	$	—	$	200

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Executive Summary

During the first quarter of 2025, the Company delivered the following operational and financial highlights:

•Net sales of $88 million, reflecting 4% growth over the prior year period, which were comprised of:

◦Net sales of Wound products of $56 million, reflecting a modest decline of 1.7% compared to the prior year period

◦Net sales of Surgical products of $32 million, reflecting an increase of 16.2% compared to the prior year period

•GAAP net income and net income margin for the first quarter of 2025 of $7 million and 8%, respectively.

•Increased cash balance to $106 million, representing a $2 million increase sequentially and a $58 million increase compared to March 31, 2024

Overview

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of experience helping clinicians manage acute and chronic wounds, MIMEDX has been dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. All of our products sold in the United States are regulated by the U.S. Food & Drug Administration (“FDA”). We apply Current Good Tissue Practices (“CGTP”) and other applicable quality standards in addition to terminal sterilization to produce our allografts.

This discussion, which presents our results for the three months ended March 31, 2025 and 2024, should be read in conjunction with the unaudited condensed consolidated financial statements and accompanying notes included in this Form 10-Q and the

financial statements and accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Results of Operations

Three Months Ended March 31, 2025 Compared to the Three Months Ended March 31, 2024


	Three Months Ended March 31,
	(in thousands)
	2025		2024		$ Change		% Change
Net sales	$	88,205	$	84,709	$	3,496	4.1	%
Cost of sales	16,558		12,987		3,571		27.5	%
Gross profit	71,647		71,722		(75)		(0.1)	%
Selling, general and administrative	59,969		55,129		4,840		8.8	%
Research and development	3,328		2,841		487		17.1	%
Investigation, restatement and related	—		311		(311)		nm
Amortization of intangible assets	99		189		(90)		(47.6)	%
Impairment of intangible assets	—		54		(54)		nm
Interest income (expense), net	506		(1,690)		2,196		nm
Other expense, net	(145)		(99)		(46)		46.5	%
Income tax provision (expense)	(1,589)		(2,348)		759		(32.3)	%
Net income from continuing operations	7,023		9,061		(2,038)		(22.5)	%

Changes noted as “nm” in the table above indicate that the percentage change is not meaningful.

Net Sales

We recorded net sales for the three months ended March 31, 2025 of $88.2 million, a $3.5 million, or 4.1%, increase compared to the three months ended March 31, 2024, in which we recognized net sales of $84.7 million.

Our sales by product line were as follows (amounts in thousands):


	Three Months Ended March 31,				Change
	2025		2024		$		%
Wound	$	56,073	$	57,049	$	(976)	(1.7)	%
Surgical	32,132		27,660		4,472		16.2	%
Total	$	88,205	$	84,709	$	3,496	4.1	%

Net sales of our Wound product portfolio were $56.1 million for the three months ended March 31, 2025, a $1.0 million or 1.7% decrease compared to $57.0 million for the three months ended March 31, 2024. The decrease was primarily driven by continued challenges associated with ongoing competitive challenges related to Medicare business in the private office and associated care settings and higher-than-expected turnover of certain of our sales team and loss of associated sales in mid-2024. The Company’s recent addition of CELERA to its product portfolio helped to partially offset these headwinds.

Net sales of our Surgical products totaled $32.1 million for the three months ended March 31, 2025, reflecting an increase of $4.5 million, or 16.2%, compared to $27.7 million for the three months ended March 31, 2024. Sales growth from certain Surgical products, particularly AMNIOFIX and AMNIOEFFECT, as well as contributions from HELIOGEN, drove this increase.

Cost of Sales and Gross Profit Margin

Cost of sales for the three months ended March 31, 2025 and 2024 was $16.6 million and $13.0 million, respectively, an increase of $3.6 million, or 27.5%, year-over-year. Gross profit margin for the three months ended March 31, 2025 was 81.2% compared to 84.7% for the three months ended March 31, 2024. The year-over-year decrease in gross margin was driven by production variances and product mix. In addition, amortization of our acquired intangible assets during the three months ended March 31, 2025 further decreased margins. There was no equivalent activity during the three months ended March 31, 2024.

Selling, General and Administrative Expense

Selling, general and administrative (“SG&A”) expense for the three months ended March 31, 2025 was $60.0 million, compared to $55.1 million for the three months ended March 31, 2024. The following table shows the composition of this expense between selling and marketing (“S&M”) and general and administrative (“G&A”) components (amounts in thousands):


	Three Months Ended March 31,
	2025		2024
Selling and marketing	$	46,861	$	44,477
General and administrative	13,108		10,652
Selling, general and administrative	$	59,969	$	55,129

Sales and marketing expenses increased $2.4 million or 5%, year over year, which was driven by increases in commissions due to higher sales and higher effective commission rates. General and administrative expenses increased $2.5 million or 23%, year over year, which was driven by incremental spend from legal and regulatory disputes in the current period, including our ongoing litigation with a competitor and several former employees.

Research and Development Expense

Our research and development (“R&D”) expense for the three months ended March 31, 2025 was $3.3 million, compared to $2.8 million for the three months ended March 31, 2024, an increase of $0.5 million, or 17.1%. R&D spend in the quarter was driven by the ongoing enrollment of our EPIEFFECT randomized clinical trial along with ongoing investments in the development of future products in our pipeline.

Amortization of Intangible Assets

Amortization expense related to intangible assets was $0.1 million for the three months ended March 31, 2025, compared to $0.2 million for the three months ended March 31, 2024, a decrease of $0.1 million or 47.6%. The decrease is due to certain intangible assets being fully amortized.

Interest Income (Expense), Net

Interest income, net was $0.5 million for the three months ended March 31, 2025 compared to net interest expense of $1.7 million for the three months ended March 31, 2024. The three months ended March 31, 2024 reflected loss on extinguishment of debt of $1.4 million resulting from the repayment and termination of a previous loan agreement. The remaining difference was driven by year-over-year decreases in outstanding borrowings and interest rates on outstanding borrowings, as well as improvements to our treasury management.

Income Tax Provision Expense

The effective tax rates for the Company were 18.5% and 20.6% for the three months ended March 31, 2025 and March 31, 2024, respectively. The effective tax rates in each period were favorably impacted by vestings of restricted stock.

Discussion of Cash Flows

Operating Activities

Net cash provided by operating activities from continuing operations during the three months ended March 31, 2025 was $5.3 million, compared to $6.8 million for the three months ended March 31, 2024. The change was primarily the result of lower collections and greater expenses during the three months ended March 31, 2025.

Investing Activities

Net cash used for investing activities during the three months ended March 31, 2025 was $0.4 million, compared to $6.0 million for the three months ended March 31, 2024. Activity for the three months ended March 31, 2024 reflects our $5.0 million investment to expand our product portfolio through the TELA and Regenity agreements. There was no equivalent activity during 2025. The remaining difference reflects a year-over-year decrease in capital expenditures.

Financing Activities

Net cash used for financing activities during the three months ended March 31, 2025 was $2.9 million. Cash used by financing activities was $33.5 million during the three months ended March 31, 2024. The cash used during the three months ended March 31, 2024 was due to the repayment of the initial $30.0 million drawing under the Revolving Credit Facility, as well as deferred financing costs and other payments made as part of the Debt Refinancing Transactions, as defined above. There was no equivalent activity during the same period in 2025. The cash used during the three months ended March 31, 2025 was primarily related to tax witholdings on vestings of restricted stock.

Liquidity and Capital Resources

We require capital for our operating activities, including costs associated with the sale of product through direct and indirect sales channels, research and development activities, compliance costs, costs to sell and market our products, regulatory fees, and legal and consulting fees in connection with ongoing litigation and other matters. We generally fund our operating capital requirements through our operating activities and cash reserves. We expect to use capital to invest in the broadening of our product portfolio, including through potential acquisitions, licensing agreements or other arrangements, the international expansion of our business and certain capital projects.

As of March 31, 2025, we had $106.4 million of cash and cash equivalents, total current assets of $200.1 million and total current liabilities of $42.6 million, reflecting a current ratio of 4.7. We had no borrowings outstanding and $75 million of availability under our Revolving Credit Facility (as defined below).

The Company is currently paying its obligations in the ordinary course of business. We believe that our cash from operating activities, existing cash and cash equivalents, and available credit under the Citizens Credit Agreement, as defined below, will enable us to meet our operational liquidity needs for the twelve months following the filing date of this Quarterly Report.

Citizens Credit Agreement

In January 2024, the Company entered into the Citizens Credit Agreement, which provided the Company with $30.0 million under the Revolving Credit Facility and $20.0 million under the Term Loan Facility. Proceeds from the initial drawings under the Credit Facilities together with cash on hand were used to repay in full the $50.0 million principal amount and other outstanding obligations under a previous loan agreement and to pay related fees, premiums, costs and expenses (collectively with the entry into the Citizens Credit Agreement and the initial borrowings thereunder, the “Debt Refinancing Transactions”). In February 2024, the Company repaid the initial $30.0 million drawing under the Revolving Credit Facility and had no outstanding borrowings under this facility as of March 31, 2025. The Term Loan Facility matures in January 2029 (the “Maturity Date”).

Contractual Obligations

There were no significant changes to our contractual obligations during the three months ended March 31, 2025 from those disclosed in the section Item 7, “Management’s Discussion and Analysis of Financial Condition and Results from Operations”, in our Annual Report on Form 10-K filed with the SEC on February 26, 2025.

Critical Accounting Estimates

In preparing financial statements, we follow accounting principles generally accepted in the United States, which require us to make certain estimates and apply judgments that affect our financial position and results of operations. We regularly review our accounting policies and financial information disclosures. A summary of critical accounting estimates in preparing the financial statements was provided in our Annual Report on Form 10-K filed with the SEC on February 26, 2025. There were no new critical accounting estimates applied in the preparation of this Form 10-Q.

Recent Accounting Pronouncements

For the effect of recent accounting pronouncements, see Note 2, Significant Accounting Policies, to the unaudited condensed consolidated financial statements contained herein.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to risks associated with changes in interest rates that could adversely affect our results of operations and financial condition. We do not hedge against interest rate risk.

The interest rate on our Term Loan Facility is determined quarterly based on the 1-month term SOFR. As of March 31, 2025, the interest rate on our Term Loan Facility was 6.7%. A 100 basis point change in SOFR would change our interest expense by $0.2 million on an annualized basis.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective at a reasonable assurance level in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the fiscal quarter ended March 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

The Company and its subsidiaries are parties to numerous claims and lawsuits arising in the ordinary course of its business activities, some of which involve claims for substantial amounts. The ultimate outcome of these suits cannot be ascertained at this time.

Item 1A. Risk Factors

There have been no material changes to the Company’s risk factors included in its 2024 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a) None.

(b) None.

(c) The following table sets forth information regarding the purchases of the Company’s equity securities made by or on behalf of the Company or any affiliated purchases (as defined in Exchange Act Rule 10b-18) during the three month period ended March 31, 2025:


	Total number of shares purchased1	Average price paid per share		Total number of shares purchased under publicly announced plan		Approximate dollar value of shares that may yet be purchased under plans or programs
January 1 - January 31, 2025	—	$	—	—		$	—
February 1 - February 28, 2025	186,242	8.30		—		—
March 1 - March 31, 2025	115,059	7.93		—		—
Total for the quarter	301,301	$	8.16	$	—	$	—

(1) Reflect net settlement of shares by the Company upon vesting of employee restricted stock units in order to satisfy tax withholding obligations.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Insider Trading Arrangements and Policies

During the three months ended March 31, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits


Exhibit Number						Description
31.1 #						Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 #						Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 #						Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 #						Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS #						XBRL Instance Document
101.SCH #						XBRL Taxonomy Extension Schema Document
101.CAL #						XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF #						XBRL Taxonomy Extension Definition Linkbase Document
101.LAB #						XBRL Taxonomy Extension Label Linkbase Document
101.PRE #						XBRL Taxonomy Extension Presentation Linkbase Document



#			Filed or furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


April 30, 2025	MIMEDX GROUP, INC.

	By:	/s/ Doug Rice
		Doug Rice
		Chief Financial Officer
		(duly authorized officer)

Get the next $MDXG alert in real time by email

Date	Price Target	Rating	Analyst
7/2/2024	$11.00	Overweight	Cantor Fitzgerald
3/7/2024	$12.00	Buy	Lake Street
10/27/2023	$12.00	Buy	Craig Hallum
10/13/2022	$7.00	Buy	Mizuho
9/14/2021	$20.00 → $8.50	Buy	HC Wainwright & Co.
7/26/2021	$23.00	Outperform	Northland Capital

SEC Form 10-Q filed by MiMedx Group Inc

Chat with this insight

Recent Analyst Ratings for $MDXG

$MDXG Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

Lake Street initiated coverage on MiMedx Group with a new price target

Craig Hallum initiated coverage on MiMedx Group with a new price target

$MDXG Press Releases

Fastest customizable press release news feed in the world

MIMEDX to Present at the BofA Securities 2025 Healthcare Conference

MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

MIMEDX Announces First Quarter 2025 Operating and Financial Results

$MDXG Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

SEC Form SC 13G filed by MiMedx Group Inc

Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

$MDXG Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

$MDXG Leadership Updates

Live Leadership Updates

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

MIMEDX Announces Appointment of Two New Independent Directors

$MDXG SEC Filings

SEC Form DEF 14A filed by MiMedx Group Inc